Modality
Vaccine
MOA
CD47i
Target
CGRP
Pathway
PI3K/AKT
NMOSDSCLCLGS
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
Jun 2017
→ Mar 2031
Phase 3Current
NCT08576427
1,609 pts·SCLC
2025-06→2027-10·Active
NCT07269616
2,545 pts·LGS
2017-06→2031-03·Active
NCT06862685
25 pts·NMOSD
2019-08→2025-05·Terminated
4,179 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-2810mo agoPh3 Readout· NMOSD
2027-10-091.5y awayPh3 Readout· SCLC
2031-03-014.9y awayPh3 Readout· LGS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Active
P3
Termina…
P3
Active
Catalysts
Ph3 Readout
2025-05-28 · 10mo ago
NMOSD
Ph3 Readout
2027-10-09 · 1.5y away
SCLC
Ph3 Readout
2031-03-01 · 4.9y away
LGS
ActiveTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08576427 | Phase 3 | SCLC | Active | 1609 | VA |
| NCT07269616 | Phase 3 | LGS | Active | 2545 | NT-proBNP |
| NCT06862685 | Phase 3 | NMOSD | Terminated | 25 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP |